Eddingpharm in-licensed greater China rights to a treatment for thrombocytopenia, a side-effect of liver disease, from Shionogi of Japan. People with thrombocytopenia suffer from a low platelet count and are usually treated with via blood transfusions to aid blood clotting. Lusutrombopag is a thrombopoietin receptor agonist, marketed in Japan as Mulpleta®, that induces the production of platelets. Eddingpharm noted that China has a chronic shortage of blood for transfusions.
Source: China Biotoday
